Dapagliflozin Suppresses Plasma Hepcidin Concentrations
Dapagliflozin Suppresses Plasma Hepcidin Concentrations
复制标题
达格列净抑制血浆铁调素浓度
作者：
H. Ghanim;J. Hejna;S. Abuaysheh;Tanvi Shah;J. Kumar;M. Batra;P. Dandona
Dapagliflzin和其他SGLT2抑制剂已知可以增加红细胞压积。一种可能的机制是糖尿和多尿以及血管腔内液体的丢失。然而，由于2型糖尿病是一种促炎状态，而且已知的红细胞生成抑制因子海普西丁在促炎状态下增加，我们调查了达格列酮抑制海普西丁浓度从而增加红细胞生成的可能性。22例肾功能正常的2型糖尿病患者(平均年龄：62.1±1.7岁)随机给予安慰剂或达格列酮10 mg/d治疗12周。达伐他汀组HbA1c从7.1±0.2%降至6.7±0.2%(PJ.M.Hejna：没有。S.Abuayshh：没有。沙阿：没有。J·库马尔：没有。M.巴特拉：演讲者9S局；赛尔夫；礼来公司。P.Dandona：咨询小组；SELF；阿斯利康。顾问；自我；阿斯利康。研究支持；自我；阿斯利康。
Dapagliflozin and other SGLT2 inhibitors are known to increase hematocrit. One possible mechanism is glycosuria and polyuria and the loss of fluid from the vascular compartment. However, since type 2 diabetes is a pro-inflammatory state and since hepcidin, a known suppressor of erythropoiesis, is increased in pro-inflammatory states, we investigated the possibility that dapagliflozin suppresses hepcidin concentrations and thus increases erythropoiesis. Twenty-two patients with type 2 diabetes and normal renal function (mean age: 62.1±1.7 years) were randomly treated with placebo or dapagliflozin 10 mg daily for 12 weeks. In the dapagliflozin group, there was a fall in HbA1c from 7.1±0.2% to 6.7±0.2% (p Disclosure H. Ghanim: None. J.M. Hejna: None. S. Abuaysheh: None. T. Shah: None. J. Kumar: None. M. Batra: Speaker9s Bureau; Self; Eli Lilly and Company. P. Dandona: Advisory Panel; Self; AstraZeneca. Consultant; Self; AstraZeneca. Research Support; Self; AstraZeneca.